134 related articles for article (PubMed ID: 17234019)
1. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
3. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
Ess SM; Szucs TD
Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of statins in coronary heart disease.
Franco OH; Peeters A; Looman CW; Bonneux L
J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
Marshall T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
[TBL] [Abstract][Full Text] [Related]
8. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
9. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
Walshe V; Nash A; Barry M
Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease.
Quist-Paulsen P; Lydersen S; Bakke PS; Gallefoss F
Eur J Cardiovasc Prev Rehabil; 2006 Apr; 13(2):274-80. PubMed ID: 16575284
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
Thorvik E; Aursnes I; Kristiansen IS; Waaler HT
Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314
[TBL] [Abstract][Full Text] [Related]
14. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
Marques-Vidal P; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):541-9. PubMed ID: 11845103
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Neyt M; De Laet C; Van Brabandt H; Franco O; Ramaekers D
Acta Cardiol; 2009 Feb; 64(1):1-10. PubMed ID: 19317290
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden.
Johansson P; Ostenson CG; Hilding AM; Andersson C; Rehnberg C; Tillgren P
Int J Technol Assess Health Care; 2009 Jul; 25(3):350-8. PubMed ID: 19619354
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
19. [Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels].
Bonneux L; Barendregt JJ
Ned Tijdschr Geneeskd; 1999 Apr; 143(15):772-5. PubMed ID: 10347637
[TBL] [Abstract][Full Text] [Related]
20. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]